Tag: vaccine
Fractional doses of yellow fever vaccines are non-inferior to standard doses in seroconversion at 28 days post-vaccination
Neel Mistry -0
1. One-fifth fractional doses from all four live attenuated yellow fever virus vaccines met the non-inferiority criterion.
2. The most common treatment-related adverse events were headache (22.2%), fatigue (13.7%), myalgia (13.3%), and self-reported fever (9.0%).
Evidence Rating Level: 1 (Excellent)
Study Rundown: Yellow fever is a mosquito-borne viral disease that is endemic...
#VisualAbstract: Special Report: Vaccines in Development- Johnson & Johnson vaccine as another frontrunner
Constance Wu -
Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists
The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its COVID-19 vaccine efforts on a single-dose replication-defective human adenovirus 26 vector (Ad26.COV2.S).1,2,3 This vector deliver recombinant SARS-CoV-2 S protein genes to human cells. While no vaccines...
#VisualAbstract: Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise
Constance Wu -
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes
With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is the chimpanzee adenovirus-vector (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.1 The University of Oxford developers of this vaccine have a partnership with AstraZeneca. This Phase 1/2...
Adenovirus-vectored ChAdOx1 nCoV-19 vaccine offers a good safety profile and strong immunogenicity against COVID-19 in older adults
Michael Pratte -
1. The ChAdOx1 nCoV-19 vaccine against COVID-19 was well-tolerated overall, with reduced reactogenicity in older adults.
2. The ChAdOx1 nCoV-19 vaccine induced a robust SARS-CoV-2 spike-antibody response and showed similar immunogenicity across all age groups after a boost dose.
Evidence Rating Level: 1 (Excellent)
Study Rundown: As the SARS-CoV-2 virus continues to...
Special Report: Vaccines in Development Part 5: Potential emerging vaccine candidates and other considerations
Jack Lennon -
Section 5: Other Promising Vaccine Candidates and Considerations
Messenger RNA (mRNA) vaccines have offered a novel methodology in the context of COVID-19, including the Pfizer/BioNTech1 and Moderna2 vaccines. Rather than placing a weak or inactivated germ into the human body, mRNA vaccines utilize host cells to make a protein that...
Special Report: Vaccines in Development Part 4: Johnson & Johnson vaccine as another frontrunner
Jack Lennon -
Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists
The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its COVID-19 vaccine efforts on a single-dose replication-defective human adenovirus 26 vector (Ad26.COV2.S).1,2,3 This vector deliver recombinant SARS-CoV-2 S protein genes to human cells. While no...
Special Report: Vaccines in Development Part 3: Oxford/AstraZeneca vaccine showing promise
Jack Lennon -
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes
With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is the chimpanzee adenovirus-vector (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.1 The University of Oxford developers of this vaccine have a partnership with AstraZeneca. This Phase...
#Visual Abstract: Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization
Constance Wu -
Section 1: Pfizer/BioNTech Vaccine First to Receive Emergency Use Authorization to Prevent COVID-19
On December 11, 2020, the U.S. Food and Drug Administration (FDA) approved for emergency use the first vaccine to prevent coronavirus disease 2019 (COVID-19).1 This vaccine includes BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA and encodes a prefusion stabilized,...
Special Report: Vaccines in Development Part 2: Moderna vaccine second to receive emergency use authorization
Jack Lennon -
Section 2: Moderna Vaccine Second to Receive Emergency Use Authorization
The FDA Advisory Committee met on December 17, 2020, ultimately recommending the Moderna vaccine’s approval for emergency use in the prevention of COVID-19. After hospitals across the U.S. began to receive batches of the Pfizer/BioNTech vaccine, Moderna has become the...
Special Report: Vaccines in Development Part 1: Pfizer/BioNTech vaccine first to receive emergency use authorization
Jack Lennon -
Section 1: Pfizer/BioNTech Vaccine First to Receive Emergency Use Authorization to Prevent COVID-19
On December 11, 2020, the U.S. Food and Drug Administration (FDA) approved for emergency use the first vaccine to prevent coronavirus disease 2019 (COVID-19).1 This vaccine includes BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA and encodes a prefusion...